Serum Sclerostin and Its Association with Bone Turnover Marker in Metabolic Bone Diseases

Table 5

Clinical characteristics of the 139 patients.

	OI ()	XLH ()	PDB ()
β-CTX (ng/L)	793.10 (433.05, 1140.00)	1616.00 (692.80, 2518.00)	1195 (643.73, 2733.25)
PTH (pg/mL)	27.62 (20.27, 45.18)	67.82 (56.72, 86.28)	40.43 (34.70, 59.81)
25OHD (ng/mL)
OC (ng/mL)	62.31 (37.16, 111.96)	66.37 (22.63, 98.18)	58.10 (20.48, 140.98)
Ca (mmol/L)
Pi (mmol/L)
ALP (U/L)	228.00 (129.75, 343.25)	307.50 (110.50, 567.00)	293.00 (167.00, 710.50)
Cr (μmol/L)
Sclerostin (pmol/L)	130.50 (96.12, 160.80)	163.40 (125.10, 238.20)	291.60 (153.42, 357.35)

BMI: body mass index; β-CTX: β-CrossLaps of type 1 collagen containing cross-linked C-telopeptide; PTH: parathyroid hormone; 25OHD: 25-hydroxyvitamin D; OC: serum osteocalcin in the form of an N-terminal midmolecule fragment; Ca: serum total calcium; Pi: serum phosphate; ALP: serum alkaline phosphatase; Cr: serum creatinine; OI: osteogenesis imperfecta; XLH: X-linked hypophosphatemia; PDB: Paget’s disease of bone. Normally distributed data are presented as the (SD), nonnormally distributed data are presented as the median (interquartile range).